Patents by Inventor Paul David Rennert

Paul David Rennert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted cancer therapy
    Patent number: 11207339
    Abstract: Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 28, 2021
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul David Rennert, John Todd Schiller
  • TARGETED CANCER THERAPY
    Publication number: 20180311269
    Abstract: Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 1, 2018
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, Aleta Biotherapeutics, Inc.
    Inventors: Roy Lobb, Paul David Rennert, John Todd Schiller
  • TARGETED CANCER THERAPY
    Publication number: 20180311374
    Abstract: Some embodiments of the present disclosure are directed to methods that include delivering to a subject a papillomavirus particle or soluble papillomavirus protein that targets a tumor, and delivering to the subject an immune cell expressing a receptor that binds to a surface antigen of the papillomavirus particle or soluble papillomavirus protein, respectively.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 1, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Aleta Biotherapeutics, Inc.
    Inventors: Roy Lobb, Paul David Rennert, John Todd Schiller